-- Accelerates development of current Sanofi licensed programs in vaccines and potential to explore other therapeutic areas -- -- Fast tracks establishment of Sanofi's recently announced mRNA Center of Excellence -- -- Full integration upgrades drug formulation capabilities and enhances US talent in a promising new technology -- PARIS and LEXINGTON, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- As part of Sanofi's endeavor to accelerate the application of messenger RNA (mRNA) to develop therapeutics and vaccines, the company has entered into a definitive agreement with Translate Bio (NASDAQ: TBIO), a clinical-stage mRNA therapeutics company, under which Sanofi will acquire all outstanding shares of Translate Bio for $38.00 per share in cash, which represents a total equity value of approximately $3.2 billion (on a fully diluted basis). The Sanofi and Translate Bio Boards of Directors unanimously approved the transaction.